CytomX Therapeutics - CTMX Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 1-year price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $11.00. On average, they expect the company's share price to reach $4.84 in the next twelve months. This suggests a possible upside of 183.3% from the stock's current price.
View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts.

CytomX Therapeutics' stock was trading at $4.33 at the start of the year. Since then, CTMX stock has decreased by 60.5% and is now trading at $1.71.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CTMX earnings forecast.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company had revenue of $17.59 million for the quarter, compared to analysts' expectations of $18.53 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 166.29% and a negative net margin of 135.65%. During the same quarter in the previous year, the firm posted ($0.32) earnings per share.

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.98%), Vanguard Group Inc. (6.87%), Tang Capital Management LLC (5.30%), Renaissance Technologies LLC (2.73%), BlackRock Inc. (2.72%) and Jacobs Levy Equity Management Inc. (1.66%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTMX stock can currently be purchased for approximately $1.71.

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $113.00 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

The company employs 174 workers across the globe.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.